A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Pfizer
Eli Lilly and Company
Bristol-Myers Squibb
Arcus Biosciences, Inc.
Pfizer
Pfizer
AstraZeneca
Tyligand Pharmaceuticals (Suzhou) Limited
Jiangsu Hansoh Pharmaceutical Co., Ltd.
ImmunityBio, Inc.
Cantargia AB
Incyte Corporation
Gilead Sciences